Trifluralin

CASRN 1582-09-8

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (13 pp, 115 K) last updated: 07/01/1989

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
7.5 x10-3 Hepatic, Hematologic Increased liver weights; increase in methemoglobin NOEL : 7.5 x10-1
mg/kg-day
100 High

Reference Concentration for Inhalation Exposure (RfC) (PDF) (13 pp, 115 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (13 pp, 115 K) last updated: 08/22/1988

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Classification is based on the induction of urinary tract tumors (renal pelvis carcinomas and urinary bladder papillomas) and thyroid tumors (adenomas/carcinomas combined) in one animal species (F344 rats) in one study. Trifluralin is structurally similar to ethalfluralin, a carcinogen in the rat.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (13 pp, 115 K)

Oral Slope Factor: 7.7 x10 -3 per mg/kg-day
Drinking Water Unit Risk: 2.2 x10 -7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Urinary, Endocrine
Tumor type(s): Combined renal pelvis carcinomas, urinary bladder papillomas and/or thyroid adenomas and carcinomas (Emmerson et al., 1980)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (13 pp, 115 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.